- Home
- LAUR vs SRRK Comparison
LAUR vs SRRK Comparison
Compare LAUR & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAUR | SRRK |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.6B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LAUR | SRRK |
|---|---|---|
| Price | $33.10 | $43.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $33.00 | ★ $47.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $1,583,936,000.00 | N/A |
| Revenue This Year | $9.66 | N/A |
| Revenue Next Year | $8.79 | $20,271.77 |
| P/E Ratio | $24.67 | ★ N/A |
| Revenue Growth | ★ 2.01 | N/A |
| 52 Week Low | $17.82 | $22.71 |
| 52 Week High | $33.81 | $48.28 |
Technical Indicators
Market Signals| Indicator | LAUR | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 63.92 | 58.29 |
| Support Level | $29.84 | $43.92 |
| Resistance Level | $33.81 | $48.28 |
| Average True Range (ATR) | 0.85 | 2.16 |
| MACD | 0.25 | -0.31 |
| Stochastic Oscillator | 81.86 | 48.35 |
Price Performance
Historical ComparisonAbout LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.